Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Key facts
- Who runs it
- Unity Health Toronto
- Where
- Augusta, Aurora, Baltimore, Chapel Hill, NC, Cincinnati, Little Rock, Los Angeles, Monkton, New Haven, Phoenix, Rochester, Salt Lake City, San Francisco, and St Louis, United StatesSee the 14 sitesAlso in 2 other countries, 5 sites
- Trial code
- Status
- Completed
- People taking part
- 2,272 people enrolled
- Started
- 8 Apr 2010
- Ended
- 30 Jun 2025
- Type of study
- Observational, 2 groups
- Record updated
- 22 April 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Definite clinical HHT diagnosis (at least 3 Curacao criteria)or genetic diagnosis of HHT or
- Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and Presence of Brain Arteriovenous Malformation
- Able to provide informed consent; Curacao criteria:
- spontaneous recurrent nosebleeds
- mucocutaneous telangiectasia at characteristic sites (lips, oral cavity or the nose)
- visceral involvement such as pulmonary, hepatic or CNS BAVM; and (d) an affected first degree relative by same criteria; Willingness
- Willingness to participate in the study and ability to give informed consent
Who cannot take part
- Patients not complying with Inclusion criteria
Where in United States
Also in 2 other countries, 5 sites
- Georgia Regents UniversityAugusta, United States
- UCHealth Pulmonary Vascular Disease Clinic - Anschutz MedicalAurora, United States
- Johns Hopkins University School Of MedicineBaltimore, United States
- University of North Carolina at Chapel HillChapel Hill, NC, United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United States
- University of Arkansas for Medical SciencesLittle Rock, United States
- David Geffen School of Medicine at University of California, Los AngelesLos Angeles, United States
- HHT Foundation International, Inc.Monkton, United States
- Yale UniversityNew Haven, United States
- Barrow Neurological InstitutePhoenix, United States
- Mayo ClinicRochester, United States
- University of UtahSalt Lake City, United States
- University of California San FranciscoSan Francisco, United States
- Washington University School of MedicineSt Louis, United States
About the trial
What the trial wants to find out
This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research. The consortium research focuses on brain blood vessel malformations in three different rare diseases.
Read full original descriptionShow less
The focus of this specific study is on Hemorrhagic Telangiectasia (HHT).
HHT is a condition characterized by blood vessel malformations, called telangiectasia and arteriovenous malformations (AVMs), occurring in the brain, nose, lungs, stomach, bowels and liver. Brain AVMs (BAVMs) in HHT are difficult to study because they are rare, affecting approximately 10% of people with HHT. While other types of BAVMs have been studied in depth, studies in the HHT population have been very small. Here, we propose the first large-scale collaboration by joining with 12 HHT Centers of Excellence in North America to perform a large study of risk factors for bleeding from BAVMs, called intracranial hemorrhage (ICH) in HHT patients.
The current standard of clinical practice across North America, is to screen all HHT patients for BAVMs with magnetic resonance imaging (MRI). If BAVMs are detected, patients are referred to a multidisciplinary neurovascular team for consideration for treatment. Treatment decisions are made on a case by case basis, balancing risks of complications from the BAVM with risks of therapy, but are limited by the few studies available in HHT. We hope that the knowledge we obtain about the risk factors for intracranial bleeding in these patients from this larger study will help us to improve the care of HHT patients.
We plan to study risk factors for rupture of BAVMs, including primarily genetics and imaging characteristics of the BAVMs. Knowledge about risk factors will help in the care and management of HHT patients. This will be achieved through the collection of health information to construct a HHT database, blood sampling and banking (through the National Institute of Neurological Disorders and Stroke [NINDS]), and through genetic analysis at the University of California San Francisco.
The 2 groups in the trial
- HHT- Brain Arteriovenous Malformation
1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and 2. Presence of Brain Arteriovenous Malformation
- HHT -NO BAVM
1\. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia (RDCRN# 6203, Protocol Version Date 07Jan10)
- Record updated
- 22 April 2026